💊 Obesity Watch: GLP-1 Pills, Trial Updates & Global Market Moves
In this week’s Obesity Updates, we we’re diving into major developments shaping the future of obesity treatment worldwide – from FDA clearances to international market expansions.
Key updates include:
🧪 Corxel begins a U.S. Phase 2 trial for its oral GLP-1 candidate, CX11
💊 RedHill’s opaganib shows potential in weight loss and glucose control
🔄 Palatin hits key milestones with its dual-mechanism combo therapy
💥 Lilly’s orforglipron achieves up to 14.7% weight loss in clinical trials
❌ Pfizer halts danuglipron after safety concerns arise
🇯🇵 Zepbound approved in Japan, shaking up the obesity drug market
🏥 Novo Nordisk partners with Hokkaido City for a national obesity model
🇨🇳 Kailera targets China’s growing need for semaglutide alternatives
🚀 Asia leads innovation in non-injectable GLP-1 obesity therapies
These breakthroughs signal a fast-changing landscape in obesity research, with Asia stepping up as a hub of innovation and U.S. biotech pivoting in response to safety signals and global market dynamics.
📢 Stay Ahead in Obesity Research!
✅ Like, share, and subscribe for weekly updates on Obesity
#ObesityResearch #GLP1 #PharmaNews #ClinicalTrials #HealthcareInnovation #LucidQuest #WeightLossScience #BiotechUpdates #ObesityTreatment #NovoNordisk #Pfizer #Lilly #Zepbound #AsiaInnovation #PublicHealth #HealthcareConsulting